Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

3 1 1 1

What is this study about?

This clinical trial is focused on studying the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in individuals with weakened immune systems. The trial will evaluate the effectiveness and safety of a medication called pritelivir, which is taken orally in the form of a tablet. The study will also involve other treatments, including Foscavir (foscarnet sodium hexahydrate), Imiquimod cream, and anhydrous cidofovir, which are used in different forms such as infusions or topical applications.

The purpose of the study is to assess how well pritelivir works in treating these specific HSV infections compared to other treatments chosen by the investigator. Participants will receive treatment for a maximum of 28 days, and the study will monitor the healing of lesions, the recurrence of the virus, and any side effects experienced by the participants. The trial will also look at how quickly the lesions heal and how long it takes for any pain associated with the lesions to stop.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the effectiveness of the treatments. The trial aims to provide valuable information on the best ways to manage acyclovir-resistant HSV infections in people with compromised immune systems, potentially leading to improved treatment options in the future.

1 joining the trial

Upon joining the trial, the participant will be informed about the study’s purpose and procedures. Consent will be obtained to ensure understanding and agreement to participate.

2 treatment initiation

The participant will begin treatment with oral pritelivir at a dosage of 100 mg once a day. This treatment is intended for those with acyclovir-resistant mucocutaneous HSV infections.

The treatment period is set for a maximum of 28 days. The participant will be monitored for any side effects or reactions to the medication.

3 monitoring and assessment

Throughout the treatment, the participant’s condition will be regularly assessed. This includes checking for healing of lesions and any new symptoms.

The participant will report any pain experienced at the lesion site, and the time taken for pain to cease will be recorded.

4 completion of treatment

At the end of the 28-day treatment period, the participant’s response to the medication will be evaluated. This includes assessing the healing of lesions and any recurrence of symptoms.

The participant will be asked to continue reporting any symptoms or side effects for a specified period after the treatment ends.

5 follow-up

Follow-up assessments will occur at 1, 2, and 3 months after the end of treatment to monitor for any recurrence of HSV infections.

The participant’s overall health and any long-term effects of the treatment will be evaluated during these follow-up visits.

Who Can Join the Study?

Participants must be immunocompromised. This means their immune system is weaker than normal due to conditions like HIV infection, organ transplants, or long-term use of medications that suppress the immune system.
Participants must be at least 16 years old. In some countries, like Canada, Germany, and Belgium, they must be at least 18 years old.
Participants must have a type of herpes infection that does not respond to a common treatment called acyclovir. This is known as acyclovir-resistant infection.
The herpes sores must be in a place where they can be easily seen and checked by a doctor.
Participants must agree to use highly effective birth control methods to prevent pregnancy during the study and for a certain time after the study ends. This applies to both men and women.
Participants must be able to understand and agree to the study’s consent form, or have a legal representative who can do so on their behalf.
Women who can become pregnant must have a negative pregnancy test before starting the study and on the first day of the study.
Participants must provide written consent to join the study. If they cannot do this themselves, a legal representative must provide consent for them.

Who Cannot Join the Study?

Patients who are not immunocompromised. Being immunocompromised means having a weakened immune system, which makes it harder for the body to fight infections.
Patients who do not have acyclovir-resistant mucocutaneous HSV infections. Acyclovir-resistant means that the herpes virus does not respond to the usual treatment with the drug acyclovir.
Patients who are not intolerant to foscarnet. Foscarnet is another medication used to treat herpes infections, and being intolerant means having adverse reactions to it.
Patients who are not within the specified age range for the study.
Patients who do not meet other specific health criteria set by the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Hopital Necker Enfants Malades	Paris	France

Other Sites

Site Name	City	Country
Algemeen Ziekenhuis Delta	Roeselare	Belgium
University General Hospital Of Heraklion	Heraklion	Greece
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico	Milan	Italy
Fondazione IRCCS Policlinico San Matteo	Pavia	Italy
Az St-Jan Brugge-Oostende A.V.	Brugge	Belgium
Centre Hospitalier Universitaire De Nantes	Nantes	France
Hopital Beaujon	Clichy	France
Usnqlehhdwqbufzbgynal Eqcym Aci	Essen	Germany
Ldhfi Gbffdyq Hzdtcxoo Oi Atvmxy	Athens	Greece
Ufotiustwj Hqtygxti Czudldr	Cologne	Germany
Czqjri Haendnkhlcu Ea Ubsvihevcokom Dc Llaxebl	Limoges	France
Ukshpzzxrgbuvuvpoment Wouqqsyic Apc	Wuerzburg	Germany

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	18.06.2021
France	Not recruiting	18.06.2021
Germany	Not recruiting	18.06.2021
Greece	Not recruiting	18.06.2021
Italy	Not recruiting	18.06.2021

Trial locations

Investigated drugs:

Pritelivir is an oral medication being studied for its effectiveness in treating herpes simplex virus (HSV) infections that are resistant to the commonly used antiviral medication, acyclovir. This trial is particularly focused on patients who have weakened immune systems and are dealing with these resistant infections. The study aims to determine how well pritelivir works over a treatment period of up to 28 days.

Acyclovir is a standard antiviral medication used to treat infections caused by the herpes simplex virus. In this trial, it serves as a comparison to pritelivir, especially in cases where the virus has become resistant to acyclovir. The goal is to see if pritelivir can be a more effective treatment option for these resistant infections.

Foscarnet is another antiviral medication that is sometimes used when acyclovir is not effective. In this trial, pritelivir is being tested for its ability to treat infections that are resistant to both acyclovir and foscarnet, or when patients cannot tolerate foscarnet. The study aims to assess the safety and effectiveness of pritelivir in these challenging cases.

Acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised individuals – This condition occurs when the herpes simplex virus (HSV) infects the skin and mucous membranes, and the virus is resistant to the antiviral medication acyclovir. It primarily affects individuals with weakened immune systems, making it difficult for their bodies to control the infection. The disease is characterized by the appearance of painful blisters or sores on the skin or mucous membranes, which can be persistent and difficult to heal. Over time, these lesions may spread or worsen, especially if the immune system remains compromised. The resistance to acyclovir complicates treatment, as the usual antiviral therapy is ineffective, requiring alternative approaches. The progression of the disease can vary, with some individuals experiencing recurrent outbreaks.

Trial ID:

2023-510088-37-00

Protocol code:

AIC316-03-II-01

NCT ID:

NCT03073967

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Pritelivir for Treating Acyclovir-Resistant Herpes Simplex Virus in Immunocompromised Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?